Fujifilm Completes Acquisition of Shenandoah Biotechnology

TOKYO, March 29, 2022: FUJIFILM Corporation today announced that FUJIFILM Irvine Scientific, Inc., a world leader in the development and manufacture of serum-free and chemically defined cell culture media for life science research, bioproduction, and cell therapy manufacturing, completed the acquisition of Shenandoah Biotechnology, Inc., a leading manufacturer of recombinant proteins. Terms of the deal were not disclosed.

Located in Warminster, Pennsylvania, Shenandoah Biotechnology manufactures recombinant proteins including cytokines and growth factors. Shenandoah Biotechnology recently launched their CTG Grade™ line of cytokines and growth factors that are manufactured according to cGMP guidelines in the Company’s new state-of-the-art, ISO 9001:2015 certified facility.

Shenandoah Biotechnology’s portfolio of recombinant proteins complements FUJIFILM Irvine Scientific, Inc.’s advanced cell culture solutions and expertise in bioprocessing, which will provide customers with a single point of access for their life science research, discovery, and cell and gene therapy needs. 

• * Please note that the contents in this website are current as of the date of the press announcement and may be subject to change without prior notice. Information in each release, including the product availability, specification, prices, contacts, are those at the time of publication.